Vertex Absorbs ViaCyte and Its Stem Cell-Based Diabetes Treatment for $320M, Clearing Out Competition

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million.